A novel neurodegenerative spectrum disorder in patients with MLKL deficiency

Soren L Faergeman1,2,3, Hayley Evans1,2, Kathrine E Attfield1,2

  • 1Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.

Insights

Complete deficiency in programmed cell death (necroptosis) due to MLKL variants causes a progressive neurodegenerative disorder in humans. This finding suggests caution for therapeutic necroptosis inhibition, highlighting potential neurological side effects.

Area of Science:

  • Molecular Biology
  • Neuroscience
  • Genetics

Background:

  • Necroptosis, an inflammatory programmed cell death executed by MLKL, is involved in infection control and various diseases.
  • Therapeutic inhibition of necroptosis is being explored for clinical applications.
  • Neurodegenerative disorders represent a significant unmet medical need.

Purpose of the Study:

  • To investigate the clinical and molecular basis of a novel neurodegenerative disorder in two siblings.
  • To determine the functional consequences of identified genetic variants in MLKL and FA2H.
  • To explore the role of necroptosis deficiency in human neurodegeneration.

Main Methods:

  • Whole genome sequencing to identify genetic variants.
  • Functional studies using patient-derived primary cells to assess MLKL deficiency and necroptosis impairment.
  • Shotgun lipidomic analysis to evaluate FA2H function.
  • Clinical and neuroimaging assessments (MRI) of affected siblings.

Main Results:

  • Two siblings with a progressive neurodegenerative disorder (paresis, ataxia, dysarthria) were identified.
  • Homozygosity for a rare haplotype revealed a frameshift variant in MLKL and an in-frame deletion in FA2H.
  • Patient cells showed impaired necroptosis due to MLKL deficiency; FA2H function was unaffected.
  • This represents the first report of complete necroptosis deficiency in humans.

Conclusions:

  • Impaired necroptosis due to MLKL deficiency is a novel mechanism contributing to a spectrum of neurodegenerative disease.
  • The disorder shares features with primary progressive multiple sclerosis and other neurodegenerative conditions.
  • Therapeutic strategies targeting MLKL for necroptosis inhibition warrant caution due to potential adverse neurological effects.